Evaluation of knowledge of Health Care Professionals on warfarin interactions with drug and herbal medicines

Mohamed N. Al-Arifi, Syed Wajid, Nawaf K. Al-Manie, Faisal M. Al-Saker, Salmeen D. Babelgaith, Yousif A. Asiri, Ibrahim Sales

ABSTRACT

Objectives: To evaluate health care professionals’ knowledge on warfarin interactions with drugs and herbs.

Methods: A self-administered questionnaire was developed to assess health care professionals’ knowledge on warfarin interactions with drug and herb. Respondents were asked to classify 15 drugs that may affect on warfarin action as “enhance”, “inhibit”, “no effect”. The study sample involved health care professionals (physicians, pharmacists and nurses) from King Salman hospital, Saudi Arabia.

Results: About 92.2% of health care professionals identified warfarin interactions with aspirin, 4.4% for warfarin and fluoxetine. Warfarin and cardiac agents (atenolol) was correctly identified by 11.1% of respondents. In warfarin -herb interactions section, the majority of respondents (66.7%) identified the interaction between green tea and warfarin. Approximately one-third of respondents (n=33) correctly classified warfarin interactions with cardamom. No significant difference was found between the health care professionals (p=0.49) for warfarin-drug interactions knowledge score and p= 0.52 for warfarin- herb interactions knowledge score.

Conclusion: This study suggests that health care professionals’ knowledge of warfarin-drug- herb interactions was inadequate. Therefore, health care professionals should receive more education programs about drug-drug/herb interactions to provide appropriate patient counseling and optimal therapeutic outcomes.

KEY WORDS: Warfarin-drug interaction, Drug interaction knowledge, Health care professionals, Saudi Arabia.

How to cite this:

Al-Arifi MN, Wajid S, Al-Manie NK, Al-Saker FM, Babelgaith SD, Asiri YA, et al. Evaluation of knowledge of Health Care Professionals on warfarin interactions with drug and herbal medicines. Pak J Med Sci. 2016;32(1):229-233.

doi: http://dx.doi.org/10.12669/pjms.321.8902

INTRODUCTION

Warfarin is the most commonly used oral anticoagulant and has been used in preventing thromboembolic events in patients with chronic arterial fibrillation, prosthetic heart valves, venous thrombosis, coronary hear disorders. Mode of action of Warfarin believes to exert its effect by lowering the amount of active vitamin K available for the activation of clotting factors II, VII, IX, and X. Use of warfarin is still limited despite the strong evidence for its clinical value. This may be due to the narrow therapeutic index, warfarin’ drug and herb interactions, and resulting in non-therapeutic anticoagulation or life-threatening hemorrhagic complications.
In many developing countries, the use of herbal medicines is common among patients with chronic diseases. In Saudi Arabia, prophetic medicine (herbal drugs) is commonly used and practiced by most physicians and the public. Nearly 70% of the public in the central part of Saudi Arabia had used practices related to prophetic medicine in their lifetime.

Herbal medicines and food interaction are currently reported as the main cause of adverse events with warfarin. Many published studies have cited that warfarin interactions with drugs and herbs are common and harmful.

Healthcare professionals’ recognition of potential drug-drug interactions (DDIs) and herb-drug interactions are essential in reducing the risk of drug-related problem because they may result in non-therapeutic anticoagulation or life-threatening hemorrhagic complications, and increased cost. Therefore, HCPs in every practice setting need to be alert in monitoring for potential warfarin interactions with drugs and herbs and advising patients regarding herb medicines to avoid when taking warfarin.

In Saudi Arabia, no study has been found focusing on the knowledge of HCPs about warfarin interactions with drug and herb. Hence, we designed the present study to assess HCPs’ knowledge about warfarin interactions with drugs and herbs.

METHODS

A cross-sectional study was undertaken between March 2014 and June 2014, to examine the HCPs’ knowledge of warfarin-drug and warfarin-herb interactions. The study was approved by the research ethics committee at College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Study location: This study was carried out at the Tertiary Government Hospital, Riyadh city, Saudi Arabia.

Study population: The population of this study was the HCPs who are working in Tertiary Government Hospital, Riyadh city, Saudi Arabia. HCPs include all doctors, nurses and pharmacists.

Sample size: The target population for this study included doctors, pharmacists and nurses working in Tertiary Government Hospital. There were approximately 600 registered HCPs who working in Tertiary Government Hospital. Out of this 150 HCPs (25%) were randomly selected from the register. Stratified random sampling was used in which HCPs were divided into subgroups (i.e. doctors nurses and pharmacists), before selection.

Survey questionnaire: Items focused on common warfarin – drug interactions and other items related to interaction of warfarin with herb were extracted from literature.

The first draft of questionnaire was reviewed by an expert panel which consist of a clinical pharmacist, a pharmacologist, and a physician, all of whom had experience in their respective fields. The questionnaire was pilot tested among eleven HCPs before distribution. The reliability test showed a Cronbach’s alpha of 0.77 for warfarin–drug interactions and 0.51 for warfarin-herb interactions.

The final questionnaire consisted of 22 items. The knowledge of warfarin- drug interactions’ section consisted of 15 multiple choices questions whereas warfarin-herb interactions’ section included 7 questions. HCPs were asked to classify the effect of each drug on warfarin action as “enhance”, “inhibit”, “no effect” or “don’t know” and asked to identify warfarin interactions with each herb as “yes”, “no” and “don’t know”. Every correct answer in each section was given one mark. The final score in each section was calculated by adding the marks scored in that section.

Statistical Analysis: The data was keyed into the Statistical Package of Social Science software version 22 (SPSS Inc., Chicago, IL, USA) for analysis. Both descriptive and analytic statistics were applied. For descriptive analysis, results were expressed as numbers, percentages and mean (± SD). The Kruskal-Wallis test was used to assess HCPs group differences at a significance level of 0.05.

RESULTS

Percentages of correct answers regarding warfarin drug-drug interactions were ranked and the curve of these ranks in each group was not normally distributed. The homogeneity of variance between the three groups (physicians, pharmacists and nurses) was tested using non-parametric Levene’s test. The test showed that the three groups have similar distribution curves (F=1.307, p>0.05). Kruskal-Wallis test showed that there is no significant difference (p>0.05) between the three groups regarding their knowledge of warfarin drug-drug interactions. For drug-herb interactions the three groups were also found to have similar distribution curves (F=0.777, p>0.05) and there was no significant difference between the groups (p>0.05) regarding this type of interactions.

Ninety HCPs returned completed questionnaire (response rate, 56.2%). Out of those 90, there were 24 physician (26.7%), 31 pharmacists (34.4%) and
35 nurses (38.7%). More than 70% of physicians and pharmacists were male. The majority of respondents had been in their practice for less than ten years (73.3%). More than half of respondents graduated from Saudi Arabia. Table-I shows the distribution of demographic data of health care professionals.

Knowledge on warfarin –drug interactions: Correct responses for warfarin-drug interaction ranged from 4.4% (n=4) for warfarin and Fluoxetine may enhance effect on warfarin action to 92.2% (n = 83) for warfarin and aspirin increases likelihood of bleeding. Table-II shows the frequency of respondents who gave correct answers.

Knowledge on warfarin–herb interactions: In this section, healthcare professionals were asked to select the most appropriate warfarin interactions with herb. Table-III shows the correct answer of respondents to warfarin-herb interactions knowledge questions. Correct responses for warfarin-herb interactions ranged from 33.3% (n=30) for warfarin and cranberry to 75.6% (n=68) for warfarin and garlic.

Warfarin-drug/herb interactions knowledge score: The Kruskal-Wallis test was used to test the differences in the knowledge of warfarin-drug interactions and warfarin–herb interactions scores among HCPs groups as shown in Tables-IV. No significant difference was found, however, between the HCPs (p=0.49) for Warfarin-drug interactions knowledge and p = 0.52 for warfarin-herb interactions knowledge score.

**DISCUSSION**

Studies on HCPs’ knowledge regarding warfarin-drug /herb interactions are limited. To our knowledge, this is the first study done to evaluate the HCPs’ knowledge about warfarin-drug/herb interactions. In this study it is clear that HCPs did not recognize all these potentially harmful warfarin-drug interactions.

### Table-I: Distribution of demographic data of health care professionals by groups.

| Characteristics       | Physician N (%) | Pharmacist N (%) | Nurse N (%) | Total N (%) |
|-----------------------|-----------------|------------------|-------------|-------------|
| Gender                |                 |                  |             |             |
| Male                  | 17(70.8)        | 22(71.0)         | 14(40)      | 53(58.9)    |
| Female                | 7(29.2)         | 9(29.0)          | 21(60)      | 37(41.1)    |
| Age(years)            |                 |                  |             |             |
| 25-35                 | 9(37.5)         | 28(90.3)         | 29(82.9)    | 66(73.3)    |
| 36-45                 | 6(25.0)         | 2(6.5)           | 5(14.3)     | 13(14.4)    |
| 46-55                 | 8(3.3)          | 1(3.2)           | 1(2.9)      | 10(11.1)    |
| More than 55          | 1(4.2)          | --               | 1(1.1)      |             |
| No.of experiences(years) |               |                  |             |             |
| Less than 10          | 9(37.5)         | 26(83.9)         | 29(82.9)    | 66(73.3)    |
| 11-20                 | 12(50.0)        | 5(16.1)          | 13(37.1)    | 49(54.4)    |
| 21-30                 | 2(8.3)          | --               | 1(2.9)      | 10(11.1)    |
| More than 30          | 1(4.2)          | --               | 1(1.1)      |             |
| Country of graduation |                 |                  |             |             |
| Saudi Arabia          | 8(33.3)         | 28(90.3)         | 13(37.1)    | 49(54.4)    |
| Egypt                 | 9(37.5)         | 1(3.2)           | 1(2.9)      | 11(12.2)    |
| Sudan                 | 3(12.5)         | 1(3.2)           | --          | 4(4.4)      |
| India                 | 1(4.2)          | 1(3.2)           | 5(14.3)     | 7(7.8)      |
| Philippine            | 2(8.3)          | --               | 15(42.9)    | 17(18.9)    |
| Bangladesh            | 1(4.2)          | --               | 1(2.9)      | 2(2.2)      |

### Table-II: Response of HCPs (pharmacists, doctors, and nurses) to the knowledge questionnaire N=90.

| No | Items                        | Doctors Correct answer N(%) | Pharmacists Correct answer N(%) | Nurses Correct answer N(%) | Total Correct answer N(%) |
|----|------------------------------|-------------------------------|---------------------------------|---------------------------|--------------------------|
| 1  | Anti inflammatory agents     |                               |                                 |                           |                          |
|    | Aspirin                      | 24(100)                       | 26(83.9)                        | 33(94.3)                  | 83(92.2)                 |
|    | Topical salicyates           | 16(66.7)                      | 15(48.4)                        | 17(48.6)                  | 48(53.3)                 |
| 2  | Cardiac agents               |                               |                                 |                           |                          |
|    | Propranolol                  | 17(70.8)                      | 15(48.4)                        | 16(45.7)                  | 48(53.3)                 |
|    | Atenolol                     | 2(8.3)                        | 4(12.9)                         | 4(11.4)                   | 10(11.1)                 |
| 3  | Gastrointestinal agents      |                               |                                 |                           |                          |
|    | Omeprazole                   | 10(41.7)                      | 17(54.8)                        | 21(60.0)                  | 48(53.3)                 |
|    | Ranitidine                   | 4(16.7)                       | 9(29)                           | 1(2.9)                    | 14(15.6)                 |
|    | Sucralfate                   | 7(29.2)                       | 5(16.1)                         | 13(37.1)                  | 25(27.8)                 |
| 4  | Antimicrobial agents         |                               |                                 |                           |                          |
|    | Ciprofloxacin                | 17(70.8)                      | 20(64.5)                        | 15(42.9)                  | 52(57.8)                 |
|    | Fluconazole                  | 13(54.2)                      | 16(51.6)                        | 14(40.0)                  | 43(47.8)                 |
|    | Azithromycin                 | 13(54.2)                      | 14(45.2)                        | 16(45.7)                  | 43(47.8)                 |
| 5  | CNS agents                   |                               |                                 |                           |                          |
|    | Fluoxetine                   | 1(4.2)                        | 2(6.5)                          | 1(2.9)                    | 4(4.4)                   |
|    | Phenytoin                    | 6(25.0)                       | 11(35.5)                        | 11(31.4)                  | 28(31.1)                 |
| 6  | Vitamin supplements          |                               |                                 |                           |                          |
|    | Multivitamin                 | 3(12.5)                       | 7(22.6)                         | 4(11.4)                   | 14(15.6)                 |
|    | Vitamin E                    | 5(20.8)                       | 7(22.6)                         | 11(31.4)                  | 23(25.6)                 |
|    | Vitamin C                    | 12(50.0)                      | 10(32.3)                        | 14(40.0)                  | 36(40.0)                 |
interactions. Among anti-inflammatory agents two interacting drugs with warfarin were potentiate the effect of warfarin, only aspirin and warfarin was correctly classified by the majority (92.2%) of HCPs. Warfarin and cardiac agents (propranolol); its moderate recognition rate (53.3%) suggests to explain the prevalence of co-prescription of oral anticoagulants and propranolol that was reported highly probable evidence that it potentiated the effect of warfarin.14

Another potentiating drug the effect of warfarin was fluconazole; its low recognition (47.8%) resulting in bleeding occur if the anticoagulant dosage is not reduced appropriately.15 In addition two drugs inhibiting the effect of warfarin including sucralfate and phenytoin; its low recognition rate (27.8% and 31.3% respectively) of the HCPs. This could lead to reduced anticoagulant response to warfarin.12,16,17 This study also found low recognition rate for atenolol, ranitidine and fluoxetine (11.1%, 15.6% and 4.4% respectively). These drugs have no effect on warfarin action.12,18,19

This study found that the HCPs’ knowledge on warfarin-drug interactions was insufficient. This finding however, varies between HCPs where pharmacists slightly higher knowledge than doctors and nurses although the difference was not significant (p=0.49). This could lead to inappropriate patient counseling, change in anticoagulant effect and adverse medical consequences. This finding is consistent with the findings from previous studies involving pharmacist, doctors and nurses. A study was conducted by Couris et al.11 among HCPs to assess their knowledge about warfarin-vitamin drug-nutrient interactions. They found that their knowledge was inadequate in drug-nutrient interactions and general nutrition. Because of different drug pair selection, findings of the present study may not be directly comparable to those of a previous study. However, these studies reported that HCPs’ knowledge of drug-drug interactions was in generally poor.20,21

Certain herbs are already known and/or potential possibly threatening interactions with warfarin, for example, ginkgo, garlic (Allium sativum), and ginseng (Panax ginseng) potentiate anticoagulant therapy and may alter bleeding times and should, therefore, not be used concomitantly with warfarin.6,14,22

The result of the current study showed that the majority of the HCPs had poor knowledge on herb-warfarin interactions. The HCPs’ knowledge on warfarin and Cranberry interaction was low recognition rate was (33.3%). The other area of weak knowledge among HCPs on warfarin and cardamom interactions 35.6% of HCPs correctly identified. About 52% of HCPs correctly classified the interaction between Ginkgo biloba and warfarin. This is low recognition rate may be resulting inappropriate patient counseling and resulting in major bleeding23,24

Table-III: Frequency of respondents who gave correct answers about herb interactions with warfarin.

| No | Items       | Doctors Correct answer N(%) | Pharmacists Correct answer N(%) | Nurses Correct answer N(%) | Total Correct answer N(%) |
|----|-------------|-----------------------------|---------------------------------|----------------------------|--------------------------|
| 1  | Green tea  | 17(70.8)                    | 23(74.2)                        | 20(57.1)                    | 60 (66.7)                |
| 2  | Garlic     | 22(91.7)                    | 21(67.7)                        | 25(71.4)                    | 68 (75.6)                |
| 3  | Ginkgo biloba | 14(58.3)                   | 20(64.5)                        | 13(37.1)                    | 47 (52.2)                |
| 4  | Grapefruit | 17(70.8)                    | 22(71.0)                        | 19(54.7)                    | 58 (64.4)                |
| 5  | Cardamom  | 7(29.2)                     | 12(38.7)                        | 13(37.1)                    | 32 (35.6)                |
| 6  | Cranberry | 8(33.3)                     | 10(32.3)                        | 12(34.3)                    | 30(33.3)                 |
| 7  | Ginseng   | 10(41.7)                    | 16(51.6)                        | 22(62.9)                    | 48(53.3)                 |

Table-IV: Warfarin-drug/herb interactions knowledge score between health care professional groups.

| Items                     | Professionals category | Mean (median) | P*value |
|--------------------------|------------------------|---------------|---------|
| Warfarin- drug interaction knowledge | Doctors | 5.6.0 (6.0) | 0.49 |
|                         | Pharmacists            | 5.7 (5.5)     |         |
|                         | Nurses                 | 5.3 (5.0)     |         |
| Herb-Warfarin interaction knowledge | Doctors | 3.9(3.5) | 0.52 |
|                         | Pharmacists            | 4.0(4)        |         |
|                         | Nurses                 | 3.5(3.0)      |         |

*Kruskal-Wallis Test.
The finding of present study may not be directly comparable to those a previous study. Because our study focused only on herb-warfarin interactions while others were among herb-drug interactions. Nevertheless, few common findings are noteworthy. A study was carried by Suchard et al. to assess the physician knowledge about herb- drug interaction. The results of this study revealed that the level of physician’ knowledge was poor.

Limitations: Our study has some limitations. Respondents were from a single hospital of central Saudi Arabia. Therefore, not representative of the entire population of health care professionals in Saudi Arabia as whole. The study did not involve dietitians or doctor of naturopathy, the two HCPs used to provide dietary advice to patients with chronic diseases. This survey can serve as a preliminary study and is helpful in understanding the knowledge of HCPs on warfarin drug- herb interactions in Saudi Arabia.

CONCLUSION

This study assessed the HCPs’ knowledge on clinically significant warfarin drug - herb interactions. This study suggests that HCPs may have insufficient ability to recognize clinically significant warfarin- drug interactions and herb-warfarin interactions. Inadequate knowledge of warfarin-drug interactions/ herb-warfarin interactions results in insufficient anticoagulation effect or bleeding complications. Therefore, additional training and integration of knowledge and expertise about drug-herb interactions among healthcare professionals is essential to provide appropriate patient counseling and optimal therapeutic outcomes.

Source of funding: None.

REFERENCES

1. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol. 2008;141(6):757–763. DOI: 10.1111/j.1365-2410.2008.07199.x
2. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest. 2004;119(4):2285–252S. DOI:10.1378/chest.119.5_suppl.228S
3. Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999;59(3):635–646.
4. Hirsh J, Dalen J, Anderson DR. Oral anticoagulants: mechanism of action clinical effectiveness and optimal therapeutic range. Chest. 2001;119(1):85–215. DOI:10.1378/chest.119.1_suppl.85
5. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events: Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29–34. DOI:10.1001/jama.1995.03530100043033
6. Sørensen JM. Herb-Drug, Food–Drug, Nutrient–Drug, and Drug–Drug Interactions: Mechanisms Involved and Their Medical Implications. J Altern Complement Med. 2002;8(3):293-308. DOI:10.1089/10755530260127989
7. Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med Principles Pract. 2012;21(5):404–428. DOI:10.1159/000343488
8. AlBedah MN, El-Olemy AT, Khalil MKM. Knowledge, attitude and practice of public in Riyadh region, Saudi Arabia, about complementary and alternative medicine. Egypt J Community Med. 2010;28(1):39–52.
9. AlBedah AM, El-Olemy AT, Khalil MKM. Knowledge and attitude of health professionals in the Riyadh region, Saudi Arabia, toward complementary and alternative medicine. J Family Community Med. 2012;19(2):93–99. DOI: 10.4103/2230-8292.98290
10. Göhl KJ, Patel JA. Herb-drug interactions: a review and study based on assessment of clinical case reports in literature. Indian J Pharmacol. 2007;39(3):129–139. DOI:10.4103/0019-5413.33432
11. Couris RR, PhD, Tataronis GR, Dalla GE, Blumberg JB, Dwyer JT. Assessment of Healthcare Professionals’ Knowledge About Warfarin-Vitamin K Drug-Nutrient Interactions. J Am Coll Nutr. 2000;19(4):439-445. DOI:10.1080/07315724.2000.10718944
12. Holbrook AM, Pereira JA, Labiris R, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095-1106. DOI:10.1001/archinternmed.165.10.1095
13. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121:676-683. DOI:10.7326/0003-4812-121-9-19941010-00009
14. Beikang GE, Zhang Z, Zuo Z. Updates on the Clinical Evidenced Herb-Warfarin Interactions. J Evid Based Complementary Altern Med. 2014; Article ID 957362. DOI:10.11515/2014/957362
15. Crussell-Porter LL, Rindone JP, Ford MA, Jaskar DW. Low – dose Flucloxacil therapy potentiates the hypoprothrombinemic response of warfarin sodium [abstract]. Arch Intern Med 1993;153(1):102-104. DOI:10.1001/archinte.1993.0001010124012
16. Mungall D, Talbert RL, Phillips C, Jaffe D, Ludden TM. Sucrealate and warfarin [letter]. Ann Intern Med. 1983;98:557.
17. Couris RR, PhD, Tataronis GR, Dalla GE, Blumberg JB, Dwyer JT. Assessment of Healthcare Professionals’ Knowledge About Warfarin-Vitamin K Drug-Nutrient Interactions. J Am Coll Nutr. 2000;19(4):439-445. DOI:10.1080/07315724.2000.10718944